STOCK TITAN

Sigilon Therapeutics to Present at Barclays Global Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Sigilon Therapeutics, Inc. (NASDAQ:SGTX) announced that its President and CEO, Rogerio Vivaldi, M.D., will present a corporate overview at the Barclays Global Healthcare Conference on March 11, 2021, at 10:55 a.m. EST. The presentation will be virtual, and a live webcast can be accessed on the company's website. Sigilon focuses on developing functional cures for chronic diseases using its Shielded Living Therapeutics™ platform, offering engineered cell-based therapies for conditions like hemophilia and diabetes. These therapies utilize Afibromer™ biomaterials to protect against immune rejection.

Positive
  • None.
Negative
  • None.

CAMBRIDGE, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that its President and Chief Executive Officer, Rogerio Vivaldi, M.D., will present a corporate overview during the Barclays Global Healthcare Conference. The presentation will take place on Thursday, March 11 at 10:55 a.m. EST, in a virtual format.

A live webcast of the presentation will be accessible under “Events and Presentations” in the Investors & Media page of the Company’s website at www.sigilon.com. A replay of the webcast will be available following the event on the Sigilon website.

About Sigilon Therapeutics
Sigilon Therapeutics seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform. Sigilon’s product candidates are non-viral engineered cell-based therapies designed to produce the crucial proteins, enzymes or factors needed by patients living with chronic diseases such as hemophilia, lysosomal disorders and diabetes. The engineered cells are protected by Sigilon’s Afibromer™ biomaterials matrix, which shields them from immune rejection and fibrosis. Sigilon was founded by Flagship Pioneering in conjunction with Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology.


FAQ

When is Sigilon Therapeutics presenting at the Barclays Global Healthcare Conference?

Sigilon Therapeutics will present on March 11, 2021, at 10:55 a.m. EST.

Who is presenting for Sigilon Therapeutics at the Barclays Global Healthcare Conference?

Rogerio Vivaldi, M.D., President and CEO, will present for Sigilon Therapeutics.

How can I watch the Sigilon Therapeutics presentation?

The presentation can be watched live via webcast on Sigilon's website under 'Events and Presentations'.

What is the focus of Sigilon Therapeutics?

Sigilon Therapeutics focuses on developing functional cures for chronic diseases using its Shielded Living Therapeutics™ platform.

What types of diseases does Sigilon Therapeutics target?

Sigilon Therapeutics targets chronic diseases such as hemophilia, lysosomal disorders, and diabetes.

Sigilon Therapeutics, Inc.

NASDAQ:SGTX

SGTX Rankings

SGTX Latest News

SGTX Stock Data

56.22M
1.49M
8.69%
54.33%
0.33%
Biotechnology
Healthcare
Link
United States
Cambridge